Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | Fedratinib in 2022 and beyond

Claire Harrison • 10 Nov 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Momelotinib Pacritinib Ruxolitinib

Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives a presentation on the current and future use of fedratinib in myeloproliferative neoplasms (MPNs) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Claire Harrison

2:12
The current challenges and unmet needs in myelofibrosis: clinical practice and trials
Claire Harrison • 29 Apr 2024
4:32
Current trials in MPN in the UK and the launch of the myMPNVoice app
Claire Harrison • 29 Apr 2024
2:05
The changing approaches to polycythemia vera: a clinical perspective
Claire Harrison • 29 Apr 2024
16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023

Related Videos

2:12
The current challenges and unmet needs in myelofibrosis: clinical practice and trials
Claire Harrison • 29 Apr 2024
2:13
Exciting agents and treatment approaches emerging in the field of myelofibrosis
Mary Frances McMullin • 28 Apr 2024
1:13
The current BSH guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
Mary Frances McMullin • 28 Apr 2024
1:46
Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals